Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of "Hold" from Brokerages

Shares of Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) have been given a consensus recommendation of "Hold" by the sixteen analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $177.0714.

A number of equities analysts have issued reports on the stock. Citigroup upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $150.00 to $200.00 in a research report on Wednesday, July 9th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their price objective for the company from $188.00 to $182.00 in a research report on Friday, May 23rd. JPMorgan Chase & Co. boosted their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Wall Street Zen upgraded shares of Charles River Laboratories International from a "buy" rating to a "strong-buy" rating in a research report on Saturday, September 13th. Finally, Evercore ISI boosted their price objective on shares of Charles River Laboratories International from $180.00 to $190.00 and gave the company an "outperform" rating in a research report on Friday, August 8th.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $155.32 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $7.64 billion, a PE ratio of -116.78, a P/E/G ratio of 4.20 and a beta of 1.47. The firm has a fifty day simple moving average of $160.27 and a two-hundred day simple moving average of $148.45. Charles River Laboratories International has a twelve month low of $91.86 and a twelve month high of $230.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.62. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm's revenue for the quarter was up .6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.80 earnings per share. Research analysts expect that Charles River Laboratories International will post 9.36 EPS for the current year.

Insider Activity

In related news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $157.60, for a total transaction of $126,080.00. Following the transaction, the executive vice president owned 24,116 shares in the company, valued at $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds have recently bought and sold shares of the business. Rothschild Investment LLC lifted its stake in shares of Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after buying an additional 144 shares in the last quarter. Brooklyn Investment Group lifted its stake in shares of Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock worth $27,000 after buying an additional 86 shares in the last quarter. Cromwell Holdings LLC lifted its stake in shares of Charles River Laboratories International by 542.9% in the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company's stock worth $27,000 after buying an additional 152 shares in the last quarter. Neo Ivy Capital Management bought a new position in shares of Charles River Laboratories International in the second quarter worth approximately $29,000. Finally, HM Payson & Co. bought a new position in shares of Charles River Laboratories International in the first quarter worth approximately $31,000. Institutional investors own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.